Exercise makes muscles better at using insulin and the liver produce less sugar—but those improvements don’t match up with changes in chemerin levels, meaning chemerin isn’t the main reason exercise helps insulin work better.
Scientific Claim
In older obese adults, 12 weeks of aerobic exercise improves peripheral insulin sensitivity by 91% (Rd/I) and reduces hepatic glucose production, but these changes are not significantly correlated with reductions in plasma chemerin levels.
Original Statement
“However, lower chemerin levels after training did not correlate with VO2max (r=0.14, P=0.46), TNF-α (r=0.13, P=0.59), peripheral insulin sensitivity (r=−0.22, P=0.26) or insulin-related HGP (r=0.19, P=0.35).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The study correctly reports lack of correlation using r-values and p-values. No causal language is used for this specific finding.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Randomized Controlled TrialLevel 1bWhether chemerin infusion blocks exercise-induced improvements in insulin sensitivity.
Whether chemerin infusion blocks exercise-induced improvements in insulin sensitivity.
What This Would Prove
Whether chemerin infusion blocks exercise-induced improvements in insulin sensitivity.
Ideal Study Design
A double-blind RCT in 50 older obese adults comparing 12 weeks of aerobic exercise with or without intravenous chemerin infusion (100 ng/mL daily), measuring Rd/I and HGP suppression via euglycemic clamp as primary endpoints.
Limitation: Infusion may not replicate physiological chemerin dynamics; systemic effects may confound tissue-specific insulin action.
Prospective Cohort StudyLevel 2bWhether individuals with higher baseline chemerin show blunted insulin sensitivity improvements after exercise.
Whether individuals with higher baseline chemerin show blunted insulin sensitivity improvements after exercise.
What This Would Prove
Whether individuals with higher baseline chemerin show blunted insulin sensitivity improvements after exercise.
Ideal Study Design
A 12-week prospective cohort of 100+ older obese adults undergoing supervised aerobic exercise, stratifying by baseline chemerin quartiles and measuring pre/post changes in Rd/I and HGP, adjusting for fat loss and fitness gain.
Limitation: Cannot prove chemerin directly inhibits insulin signaling pathways.
In Vitro Cell StudyLevel 5Whether chemerin impairs insulin-stimulated glucose uptake in human skeletal muscle cells.
Whether chemerin impairs insulin-stimulated glucose uptake in human skeletal muscle cells.
What This Would Prove
Whether chemerin impairs insulin-stimulated glucose uptake in human skeletal muscle cells.
Ideal Study Design
Primary human skeletal muscle cells from older obese donors treated with recombinant chemerin (0–200 ng/mL) and insulin (100 nM), measuring GLUT4 translocation, Akt phosphorylation, and glucose uptake.
Limitation: Does not reflect in vivo muscle perfusion, neural input, or systemic hormone interactions.
Evidence from Studies
Supporting (1)
Exercise-induced lowering of chemerin is associated with reduced cardiometabolic risk and glucose-stimulated insulin secretion in older adults
The study found that exercise helped older obese adults process sugar better and reduced liver sugar production — just like the claim says. It also found a hormone called chemerin went down, but that drop wasn’t tied to the sugar improvements, which matches the claim too.